Dry powder formulation of simvastatin

Bibliography

• Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007;19(1):83-8
   PubMed Web of Science ®Google Scholar
• Barker AF. Bronchiectasis. N Engl J Med 2002;346(18):1383-93
   PubMed Web of Science ®Google Scholar
• Yang Y, Tsifansky MD, Shin S, et al. Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng 2011;108(6):1441-9
   PubMed Web of Science ®Google Scholar
• Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003;2(7):517-26
   PubMed Web of Science ®Google Scholar
• Endo A, Tsujita Y, Kuroda M, Tanzawa K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 1977;77(1):31-6
   PubMedGoogle Scholar
• Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348(9034):1079-82
   PubMed Web of Science ®Google Scholar
• McAuley DF, O’Kane CM, Craig TR, et al. Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury. BMC Pulmonary Med 2013;13:47
   PubMed Web of Science ®Google Scholar
• Grommes J, Vijayan S, Drechsler M, et al. Simvastatin reduces endotoxin-induced acute lung injury by decreasing neutrophil recruitment and radical formation. PLoS One 2012;7(6):e38917
   PubMed Web of Science ®Google Scholar
• Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61(8):729-34
   PubMed Web of Science ®Google Scholar
• Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22(7):1194-9
   PubMed Web of Science ®Google Scholar
• Blamoun A, Batty G, DeBari V, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008;62(9):1373-8
   PubMed Web of Science ®Google Scholar
• Marin L, Traini D, Bebawy M, et al. Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies. Eur J Pharm Biopharm 2013;84(3):566-72
   PubMed Web of Science ®Google Scholar
• Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002;23(10):482-7
   PubMed Web of Science ®Google Scholar
• Marin L, Colombo P, Bebawy M, et al. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv 2011;8(9):1205-20
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McKeown ST, O’Kane CM, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009;179(12):1107-14
   PubMed Web of Science ®Google Scholar
• Si X-B, Zhang S, Huo L-Y, et al. Statin therapy does not improve lung function in asthma: a meta-analysis of randomized controlled trials. J Int Med Res 2013;41(2):276-83
   PubMed Web of Science ®Google Scholar
• Cowan DC, Cowan JO, Palmay R, et al. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax 2010;65(10):891-6
   PubMed Web of Science ®Google Scholar
• Menzies D, Nair A, Meldrum KT, et al. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007;119(2):328-35
   PubMed Web of Science ®Google Scholar
• Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010;392(1):1-19
   PubMedGoogle Scholar
• Crompton GK. Dry powder inhalers: advantages and limitations. J Aerosol Med 1991;4(3):151-6
   PubMedGoogle Scholar
• Haghi M, Young PM, Traini D, et al. Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm 2010;36(10):1207-14
   PubMed Web of Science ®Google Scholar
• Ong HX, Traini D, Bebawy M, Young PM. Epithelial profiling of antibiotic controlled release respiratory formulations. Pharm Res 2011;28(9):2327-38
   PubMed Web of Science ®Google Scholar
• Ong HX, Traini D, Ballerin G, et al. Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases. AAPS J 2014;16(2):269-80
   PubMed Web of Science ®Google Scholar
• Rutland J, Cole PJ. Nasal mucociliary clearance and ciliary beat frequency in cystic fibrosis compared with sinusitis and bronchiectasis. Thorax 1981;36(9):654-8
   PubMed Web of Science ®Google Scholar
• Ong HX, Traini D, Salama R, et al. The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia. Mol Pharm 2013;10(8):2915-24
   PubMedGoogle Scholar
• Murtaza G. Solubility enhancement of simvastatin: a review. Acta Pol Pharm 2012;69(4):581-90
   PubMed Web of Science ®Google Scholar
• Young PM, Price R, Tobyn MJ, et al. Effect of humidity on aerosolization of micronized drugs. Drug Dev Ind Pharm 2003;29(9):959-66
   PubMed Web of Science ®Google Scholar
• Giles CH, MacEwan T, Nakhwa S, Smith D. 786. Studies in adsorption. Part XI. A system of classification of solution adsorption isotherms, and its use in diagnosis of adsorption mechanisms and in measurement of specific surface areas of solids. J Chem Soc 1960;3973-93
   Google Scholar
• Alvarez-Lueje A, Valenzuela C, Squella JA, Nunez-Vergara LJ. Stability study of simvastatin under hydrolytic conditions assessed by liquid chromatography. J AOAC Int 2005;88(6):1631-6
   PubMed Web of Science ®Google Scholar
• Communities OfOPotE, Jowitt R, Wagstaffe PJ, Commission of the European Communities. Directorate-General for Science R, Development, Reference CotECCBo: Certification of the Water Content of Microcrystalline Cellulose (Mcc) at 10 Water Activities: Office for Official Publications of the European Communities. 1989
   Google Scholar
• Andersen I, Camner P, Jensen PL, et al. A comparison of nasal and tracheobronchial clearance. Arch Environ Health 1974;29(5):290-3
   PubMed Web of Science ®Google Scholar
• Ong HX, Traini D, Young PM. Pharmaceutical applications of the Calu-3 lung epithelia cell line. Expert Opin Drug Deliv 2013;10(9):1287-302
   PubMed Web of Science ®Google Scholar
• Chen YJ, Chen P, Wang HX, et al. Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway. Int Immunopharmacol 2010;10(6):685-93
   PubMed Web of Science ®Google Scholar
• Lora JM, Zhang DM, Liao SM, et al. Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an IkappaB kinase beta-dependent mechanism. J Biol Chem 2005;280(43):36510-17
   PubMed Web of Science ®Google Scholar
• Li D, Gallup M, Fan N, et al. Cloning of the amino-terminal and 5′-Flanking region of the humanMUC5AC mucin gene and transcriptional up-regulation by bacterial exoproducts. J Biol Chem 1998;273(12):6812-20
   PubMed Web of Science ®Google Scholar
• Lambert D, O’Neill CA, Padfield PJ. Depletion of Caco-2 cell cholesterol disrupts barrier function by altering the detergent solubility and distribution of specific tight-junction proteins. Biochem J 2005;387(Pt 2):553-60
   PubMedGoogle Scholar
• Sugiura H, Koarai A, Ichikawa T, et al. Increased 25-hydroxycholesterol concentrations in the lungs of patients with chronic obstructive pulmonary disease. Respirology 2012;17(3):533-40
   PubMed Web of Science ®Google Scholar
• McDonald JG, Russell DW. Editorial: 25-Hydroxycholesterol: a new life in immunology. J Leukoc Biol 2010;88(6):1071-2
   PubMed Web of Science ®Google Scholar
• Yeganeh B, Emilia W, Sudharsana RA, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther 2014;143(1):87-110
   PubMed Web of Science ®Google Scholar